10-Q: Vericel Reports Strong Revenue Growth Driven by MACI and NexoBrid, Despite Widening Net Loss

Vericel Corporation announced a significant increase in total revenue for the first half of 2025, fueled by strong performance in its MACI and NexoBrid products, though the company's net loss widened due to increased operating expenses.

Summary

• Total revenue for the six months ended June 30, 2025, increased by 11.4% to $115.8 million, up from $103.9 million in the same period of 2024.
• MACI product sales grew by 18.3% to $99.8 million for the first half of 2025, compared to $84.3 million in 2024, driven by volume and price growth.
• NexoBrid sales more than doubled, increasing by 107.9% to $2.5 million in the first half of 2025, up from $1.2 million in 2024, reflecting volume growth in its early commercial launch.
• Epicel sales decreased by 26.3% to $13.6 million for the six months ended June 30, 2025, down from $18.4 million in 2024, primarily due to lower volume.
• Gross profit increased by 15.2% to $82.9 million for the first half of 2025, compared to $72.0 million in 2024, benefiting from MACI revenue growth and a fixed manufacturing cost structure.
• Net loss for the six months ended June 30, 2025, widened to $11.8 million, a 38.1% increase from a net loss of $8.5 million in the prior year period.
• Loss from operations increased by 28.9% to $14.8 million for the first half of 2025, compared to $11.5 million in 2024.
• Selling, general, and administrative (SG&A) expenses rose by 20.2% to $83.7 million for the first half of 2025, primarily due to higher headcount, employee expenses (including stock compensation), increased marketing programs, sales activity, and facility costs related to the new Burlington, Massachusetts facility.
• Research and development (R&D) expenses slightly increased by 1.5% to $14.0 million for the first half of 2025, mainly due to higher headcount and employee expenses, partially offset by lower MACI Arthro project costs in 2024.
• Cash and cash equivalents stood at $80.5 million as of June 30, 2025, with total investments of $83.7 million.
• Net cash provided by operating activities decreased to $14.8 million for the six months ended June 30, 2025, from $25.7 million in the same period of 2024, primarily due to increased accounts receivable and decreases in accounts payable and accrued expenses.

Sentiment

Score: 6

Explanation: The company demonstrates strong top-line revenue growth, particularly in its key MACI and emerging NexoBrid products, and is actively pursuing strategic product expansions (MACI Arthro, MACI Ankle, NexoBrid pediatric indication). However, the significant increase in net loss and operating expenses, coupled with a decrease in cash provided by operating activities, indicates a worsening profitability trend and increased cash burn from operations. While strategic initiatives are positive for long-term potential, the short-term financial performance shows deterioration.

Positives

• Total revenue increased by 11.4% for the six months ended June 30, 2025, demonstrating overall business growth.
• MACI product sales showed robust growth of 18.3%, driven by both volume and price increases.
• NexoBrid sales more than doubled (107.9% increase), indicating strong early commercial traction for the burn care product.
• Gross profit improved by 15.2%, reflecting efficient cost management relative to revenue growth.
• The FDA approved a supplemental Biologics License Application (sBLA) in August 2024, expanding the MACI indication to include arthroscopic delivery (MACI Arthro), which is expected to increase ease of use for physicians and accelerate patient recovery.
• The target surgeon base for MACI has been expanded from 5,000 to 7,000 with the introduction of MACI Arthro, indicating a larger market opportunity.
• The FDA authorized the expansion of NexoBrid's indication to include pediatric patients in August 2024, significantly broadening its addressable market in burn care.
• The Burlington, Massachusetts manufacturing facility is substantially complete, with office space already in use, and is expected to become the primary manufacturing facility for MACI and Epicel once validated.
• The company maintains ample supply of NexoBrid at its U.S.-based third-party logistics provider, mitigating immediate supply chain risks from Middle East conflicts.
• The company believes its current cash, cash equivalents, investments, and available borrowing capacity will be sufficient to support operations for at least 12 months from the filing date.

Negatives

• Net loss widened significantly by 38.1% to $11.8 million for the six months ended June 30, 2025, compared to the prior year.
• Loss from operations increased by 28.9%, indicating higher operational costs relative to revenue.
• Selling, general, and administrative expenses increased substantially by 20.2%, contributing to the widening net loss.
• Epicel sales decreased by 26.3%, indicating a decline in volume for one of the company's key products.
• Net cash provided by operating activities decreased by 42.4% to $14.8 million for the six months ended June 30, 2025, compared to $25.7 million in the prior year, primarily due to an increase in accounts receivable and a decrease in accounts payable and accrued expenses.

Risks

• Ongoing and evolving conflicts in the Middle East region involving Israel could disrupt MediWound's ability to manufacture and supply NexoBrid, as its facilities are in Yavne, Israel, and raw materials are sourced from Taiwan.
• Inadequate funding or other disruptions at the FDA and other government agencies could hinder their ability to hire and retain key personnel, delay regulatory approvals (e.g., MACI Ankle clinical trial, Burlington facility qualification), or prevent timely development/commercialization of new products.
• Potential changes in U.S. federal government budgetary priorities and spending, including executive actions like the Department of Government Efficiency, could adversely affect funding and staffing levels at the FDA, impacting review and approval processes.
• Layoffs or resignations of FDA employees, particularly those with responsibility for drugs and biologics, could significantly delay interactions with the FDA and impact business operations.
• Uncertainty regarding how the new presidential administration in 2025 will modify or revise FDA requirements and policies could affect product approvals.
• The company is subject to risks common to the life sciences industry, including development by competitors of new technological innovations, dependence on key personnel, and protection of proprietary technology.
• If revenues decline for a sustained period, the company may need to access additional capital, which may not be obtainable on acceptable terms or at all, potentially adversely affecting shareholder holdings or rights.
• Concentration of credit risk exists with cash, cash equivalents, and investments in marketable debt securities, as deposits may exceed FDIC insurance coverage.
• Uncertainties associated with future revenue, growth, market penetration for MACI, MACI Arthro, Epicel, and NexoBrid, and the ability to sustain profitability and scale manufacturing operations.
• Potential fluctuations in sales and volumes and results of operations over the course of the year due to seasonality (e.g., MACI sales typically stronger in Q4).
• Changes in third-party coverage and reimbursement, including healthcare reform measures and private payor initiatives, could impact product sales.
• Supply chain disruptions or other events affecting the ability to manufacture MACI or Epicel, or MediWound's ability to supply NexoBrid, could impact customer demand.
• Negative impacts on the global economy and capital markets resulting from geopolitical conflicts (e.g., Ukraine, Middle East) and lingering effects of adverse developments affecting financial institutions.

Future Outlook

The company anticipates continued growth opportunities for MACI with the introduction of MACI Arthro and the potential expansion into ankle cartilage repair, with a clinical trial expected to begin in the second half of 2025. NexoBrid is expected to continue its strong volume growth, benefiting from its expanded pediatric indication and potential to change the standard of care for eschar removal. The Burlington manufacturing facility is nearing full validation and will become the primary manufacturing site for MACI and Epicel. The company expects current cash, cash equivalents, investments, and available borrowing capacity to be sufficient to support operations for at least 12 months.

Management Comments

• "We believe that the availability of MACI Arthro provides a significant growth opportunity for the overall MACI business."
• "If approved, we believe MACI's label expansion allowing its use to repair cartilage defects in the ankle will be a significant long-term growth driver for the product in the coming years."
• "NexoBrid has the potential to change the standard of care for eschar removal with respect to hospitalized burn patients and treat a significant addressable market in the U.S."
• "The expansion of our target addressable market supports a broader commercial footprint, and we believe that this may help drive both increased NexoBrid use as well as increased Epicel awareness throughout the burn care space."
• "We expect that current or future tariffs will have an insignificant impact on our cost of goods sold and gross margin moving forward."
• "We believe that our current cash on hand, cash equivalents, investments, and available borrowing capacity will be sufficient to support our current operations through at least 12 months from the issuance of the condensed consolidated financial statements included in this report."

Industry Context

Vericel operates in the specialized biopharmaceutical sector, focusing on advanced therapies for sports medicine and severe burn care. The expansion of MACI's indication to include arthroscopic delivery and the planned MACI Ankle clinical trial align with broader trends in minimally invasive procedures and market expansion within orthopedics. The pediatric indication for NexoBrid positions the company to address a larger segment of the burn care market, potentially shifting standard treatment protocols. The company's reliance on a third-party manufacturer in Israel for NexoBrid highlights geopolitical risks common in global supply chains for specialized biologics.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks. Therefore, a direct comparison to industry standards is not possible based solely on the provided content.

Corporate Governance

Stakeholder Impact

• Shareholders: Experienced a widening net loss, but also saw strong revenue growth in key products and strategic advancements that could drive future value. Director compensation changes and stock-based compensation impact equity.
• Employees: Higher headcount and increased employee expenses, including stock-based compensation, indicate continued investment in the workforce.
• Customers (Hospitals/Patients): Benefit from expanded treatment options with the FDA approval of MACI Arthro for arthroscopic delivery and NexoBrid's expanded indication to include pediatric patients.
• Suppliers: MediWound Ltd. remains a critical supplier for NexoBrid, with potential supply chain risks due to geopolitical conflicts in the Middle East.

Next Steps

• Initiate a MACI Ankle clinical trial beginning in 2025 to evaluate its use for cartilage damage in the ankle.
• Continue validation of the Burlington, Massachusetts facility's manufacturing component to become the primary manufacturing site for MACI and Epicel.
• Monitor the ongoing and evolving conflicts in the Middle East region involving Israel for potential impacts on NexoBrid supply from MediWound.
• Evaluate the impact of new accounting standards, ASU 2023-09 (Improvements to Income Tax Disclosures) and ASU 2024-03 (Disaggregation of Income Statement Expenses), on future disclosures and financial statements.

Key Dates

Recommendation

While Vericel demonstrates strong revenue growth in its core products (MACI and NexoBrid) and is making significant strategic advancements with product expansions and manufacturing facility development, the substantial increase in net loss and operating expenses, coupled with a decrease in cash from operations, raises concerns about short-term profitability and cash flow efficiency. The long-term growth potential is evident, but the current financial performance indicates a period of heavy investment that is impacting the bottom line. A 'hold' recommendation is appropriate to observe if these investments translate into improved profitability and cash generation in future periods, balancing the strong top-line performance with the widening losses.

Keywords

Biopharmaceutical, Cell Therapy, Sports Medicine, Burn Care, MACI, Epicel, NexoBrid, Cartilage Repair, Skin Replacement, Eschar Removal, FDA Approval, Quarterly Report, Revenue Growth, Net Loss, Operating Expenses, Clinical Trials, Manufacturing Facility, Biologics, Orphan Product